A Study Comparing 1 Subcutaneous Dose Regimen of Fremanezumab Versus Placebo for the Prevention of PPTH

Inclusion Criteria:

- The patient has a body weight is greater than 99 lbs.

- Traumatic injury to the head has occurred, defined as a structural or functional
injury resulting from the action of external forces.

- The patient has a diagnosis of PPTH

- The patient is not using preventive medications for headache

- Women of childbearing potential whose male partners are potentially fertile (ie, no
vasectomy) must use highly effective birth control methods for the duration of the
study. Men must be sterile or, if they are potentially fertile or reproductively
competent (ie, not surgically or congenitally sterile) and their female partners are
of childbearing potential, must use, together with their female partners, acceptable
birth control methods for the duration of the study.

NOTE- Additional criteria apply, please contact the investigator for more information

Exclusion Criteria:

- The patient has a previous history of brain imaging showing evidence of intracerebral
hemorrhage, subdural or epidural hematomas, or subarachnoid hemorrhage as a
consequence of the traumatic head injury.

- The patient has PPTH attributed to craniotomy.

- The patient has whiplash with only neck pain and no persistent headache >3 months
after whiplash.

- The patient is using analgesic medications containing opioids (including codeine) or a
barbiturate on average more than 15 days per month.

- The patient is currently using or has prior exposure to any calcitonin gene-related
peptide (CGRP) antibody, any antibody to the CGRP receptor.

- The patient has received onabotulinmumtoxinA (eg, Botox, Dysport) application in the
head or neck during the previous 3 months before screening.

- The patient has been implanted with any devices for headache prophylaxis during the
previous 3 months before screening.

- The patient has been treated with a nerve block for head and/or neck during the
previous 3 months before screening.

- The patient is a pregnant or lactating woman or plans to become pregnant during the
study.

NOTE- Additional criteria apply, please contact the investigator for more information